Regeneron Takes Full Libtayo Rights As March Into Oncology Progresses
The company will pay $900m upfront to buy Sanofi's stake in the PD-1 inhibitor, which is a cornerstone of Regeneron's strategy to build an oncology portfolio.
You may also be interested in...
The US biotech has nabbed a deal with Regeneron to develop bispecific cancer therapies by combining their respective technology platforms, getting $30m upfront in a positive twist of fate following a recent clinical trial challenge.
Regeneron's PD-1 inhibitor was approved by the US FDA in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer.
The costimulatory bispecific antibody REGN5678, meant to turn “cold” prostate cancer tumors “hot” and vulnerable to PD-1 inhibitors, showed early signs of efficacy combined with Libtayo.